# Shani Paluch–Shimon

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/shani-paluch-shimon/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,492 |
| Field | Breast Cancer Treatment Studies |
| h-index | 44 |
| i10-index | 78 |
| Last Known Institution | Hebrew University of Jerusalem |
| OpenAlex ID | https://openalex.org/A5001211980 |
| ORCID iD | https://orcid.org/0000-0002-6677-2199 |
| Works | 196 |

## Researcher papers

- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://scholariq.org/papers/esmo-clinical-practice-guideline-for-the-diagnosis-staging-and-treatment-of/)
- [5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)](https://scholariq.org/papers/5th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-5/)
- [4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)](https://scholariq.org/papers/4th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-4/)
- [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer](https://scholariq.org/papers/updated-results-from-monaleesa-2-a-phase-iii-trial-of-first-line-ribociclib-plus/)
- [Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study](https://scholariq.org/papers/pembrolizumab-monotherapy-for-previously-treated-metastatic-triple-negative/)
- [Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer](https://scholariq.org/papers/association-of-type-and-location-of-i-brca1-i-and-i-brca2-i-mutations-with-risk/)
- [Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study](https://scholariq.org/papers/adjuvant-abemaciclib-combined-with-endocrine-therapy-for-high-risk-early-breast/)
- [進行性乳癌のためのESO-ESMO国際コンセンサスガイドライン第四版(ABC 4)](https://scholariq.org/papers/eso-esmo-abc-4/)
- [6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)](https://scholariq.org/papers/6th-and-7th-international-consensus-guidelines-for-the-management-of-advanced/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Risks and Factors](https://scholariq.org/topics/cancer-risks-and-factors/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Hebrew University of Jerusalem](https://scholariq.org/institutions/hebrew-university-of-jerusalem/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.